Substance Use Disorder Treatment in the Time of COVID
UMass Chan Affiliations
Lamar Soutter LibraryDocument Type
PresentationPublication Date
2021-01-28Keywords
Massachusetts Consultation Service for the Treatment of Addiction and PainMCSTAP
Substance Use Disorder
SUD
Opioid Use Disorder
OUD
Substance Use Disorder Treatment
Substance Use Disorder Treatment during COVID
Addiction Treatment During COVID
Library and Information ScienceMedicine and Health SciencesPublic HealthSubstance Abuse and Addiction
Metadata
Show full item recordAbstract
Primary care clinicians face many challenges when addressing the complex needs of patients with chronic pain, substance use disorders or both. Over the last 10 months, the SARS-CoVID-2 pandemic has both increased and changed the challenges that healthcare providers face. Massachusetts Consultation Service for the Treatment of Addiction and Pain (MCSTAP) is a free service that helps doctors and other clinicians meet these challenges by increasing their capacity for, and comfort in, using evidence-based practices to screen, diagnose, treat and manage the care of these patients. MCSTAP provides on-demand physician consultation on safe prescribing and managing the care of patients with chronic pain and/or SUD. Join us for a webinar to learn about the innovative services that MCSTAP provides. Christopher Shanahan MD MPH FACP will share his knowledge about why and experience about how MCSTAP was created. You will learn about how SARS-CoVID-2 pandemic has changed SUD treatment and prescribing protocols. Currently, the SARS-CoVID-2 pandemic has presented serious and life-threatening challenges to both patients and to their clinicians. After attending this webinar, participants will: Understand the bidirectional relationship of SARS-Cov-2 pandemic & the epidemic U.S. Substance Use on identification & treatment of physical, mental health & Substance Use Disorders (SUD) e.g. opioid crisis Describe components & impact of Social Determinants of Health (SDOH) on care of individuals with SUD & impact on the risk for & clinical outcomes of SARS-CoV-2 infection Employ Intersectionality to identify/analyze key areas of need & potential for high impact & then develop/implement evidence-based & innovative solutions.DOI
10.13028/zba8-f315Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37559Related Resources
https://youtu.be/lTpjz9_I07YDistribution License
http://creativecommons.org/licenses/by/4.0/Scopus Count
Collections
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Integrating tobacco dependence treatment and tobacco-free standards into addiction treatment: New Jersey's experienceNew Jersey was the first State to require that all residential addiction treatment programs assess and treat patients for tobacco dependence and maintain tobacco-free facilities (including grounds). An evaluation of this policy change found that tobacco dependence treatment can be successfully integrated into residential substance abuse treatment programs through policy regulation, training, and the provision of nicotine replacement therapy (NRT) (Williams et al. 2005). Many other addiction treatment agencies (both residential and outpatient) around the country now have implemented or are planning to implement similar policies to ensure that their patients receive appropriate assessment and treatment of their tobacco dependence while receiving treatment for addiction to other substances. This paper aims to summarize the lessons learned from the experience in New Jersey.
-
Treatment of patients with substance use disorders, second edition. American Psychiatric AssociationDouglas M. Ziedonis co-authored this practice guideline as a member of the Work Group on Substance Abuse Disorders. See article for complete list of authors.
-
Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizationsOBJECTIVES: This study examined organization-level characteristics associated with the accessibility of outpatient addiction treatment. METHODS: Program directors and clinical supervisors from a nationally representative panel of outpatient substance abuse treatment units in the United States were surveyed in 1990, 1995, and 2000. Accessibility was measured from clinical supervisors' reports of whether the treatment organization provided "treatment on demand" (an average wait time of 48 hours or less for treatment entry), and of whether the program turned away any patients. RESULTS: In multivariable logistic models, provision of "treatment on demand" increased two-fold from 1990 to 2000 (OR, 1.95; 95 percent CI, 1.5 to 2.6), while reports of turning patients away decreased nonsignificantly. Private for-profit units were twice as likely to provide "treatment on demand" (OR, 2.2; 95 percent CI, 1.3 to 3.6), but seven times more likely to turn patients away (OR, 7.4; 95 percent CI, 3.2 to 17.5) than public programs. Conversely, units that served more indigent populations were less likely to provide "treatment on demand" or to turn patients away. Methadone maintenance programs were also less likely to offer "treatment on demand" (OR, .65; 95 percent CI, .42 to .99), but more likely to turn patients away (OR, 2.4; 95 percent CI, 1.4 to 4.3). CONCLUSIONS: Although the provision of timely addiction treatment appears to have increased throughout the 1990s, accessibility problems persist in programs that care for indigent patients and in methadone maintenance programs.
